View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.


PER Pulse™ Recaps for Community Practice Connections™: 11th Annual New York Lung Cancer Symposium®

This activity is supported by educational grants from Ariad Pharmaceuticals, Inc., Astellas, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Lilly, Merck Sharp & Dohme Corp., Novartis, and Pfizer.

For further information concerning Lilly grant funding, visit

Community Practice Connections™: 11th Annual New York Lung Cancer Symposium®

Release Date: February 28, 2017
Expiration Date: February 28, 2018
Media: Internet - based


Activity Overview

Community Practice Connections™: 11th Annual New York Lung Cancer Symposium® features a case-based discussion of current and developing therapies in lung cancer treatment, including inhibition of ALK and EGFR, immunotherapy, and chemotherapy for patients with non–small cell lung cancers (NSCLCs). Interactive clinical vignettes are followed by short video interviews with leading lung cancer experts and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians engaged in the care of patients with NSCLCs.

CME/CE Activity Table of Contents

  • Module 1: ALK-rearranged NSCLC
  • Module 2: EGFR Mutation-positive NSCLC
  • Module 3: Advanced, Squamous NSCLC
  • Module 4: Metastatic Lung Adenocarcinoma Without Targetable Oncogenic Drivers

Requirements for Successful Completion

  • Once you begin the activity, please answer the demographic questions. This will allow you to proceed to the activity.
  • This activity contains one or more interactive questions. You may move forward through the activity; however, you may not go back to change answers or review content until you finish the activity.
  • At the end of the activity, an Educational Content link will be available for you to download content in PDF format for your reference.
  • If you close the Web browser after you complete the activity, the Educational Content link will disappear and you will need to review the activity in its entirety to once again access the link.
  • In order to receive a CME certificate, participants must complete the activity.
  • Click on the Request Credits link at the end of the activity. Complete the posttest and pass with a score of 70% or higher, complete the evaluation, and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer.  Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  • Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer
  • Use tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced non–small cell lung cancer (NSCLC)
  • Discuss current and emerging roles for single agent and combination immunotherapeutic strategies in the management of advanced lung cancers
  • Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care
  • Assess evolving data sets concerning the use of ALK inhibition in front-line and subsequent lines of care in advanced NSCLC
  • Explain clinical trial evidence and their application concerning VEGF axis targeting in advanced NSCLC
  • Explain the role of chemotherapeutic strategies as a method to personalize care in patients with lung cancer
  • Integrate personalized approaches to manage challenging cases in advanced lung cancer settings

Faculty, Staff, and Planners' Disclosures


Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Smilow Cancer Hospital
New Haven, CT

Disclosure: Grant/Research Support: Genentech, Merck; Consultant: AstraZeneca, Eli Lilly, Genentech/Roche, Merck,Pfizer; Scientific Advisory Boards: Kolltan.

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant/Research Support: PUMA, Pfizer, Genentech; Consultant: AstraZeneca, Ariad, Roche/Genentech, Array.

Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Albert Einstein College of Medicine
Deputy Director, Albert Einstein Cancer Center
Bronx, NY

Disclosure: Grant/Research Support: National Cancer Institute; Consultant: AstraZeneca, Clovis, Roche/Genentech, Boehringer Ingelheim, Lilly, Adgero; Stock/Shareholder: Adgero.

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
Founder & President, GRACE (
Seattle, WA

Disclosure: Consultant: Ariad, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech/Roche, Guardant Health, Merck, Novartis, Trovagene; Speaker’s Bureau: Ariad, Genentech/Roche, Lilly.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Staff and Planners’ Disclosures

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By